WO2013132512A1 - Composition pharmaceutique de chlorhydrate de raloxifène - Google Patents

Composition pharmaceutique de chlorhydrate de raloxifène Download PDF

Info

Publication number
WO2013132512A1
WO2013132512A1 PCT/IN2012/000588 IN2012000588W WO2013132512A1 WO 2013132512 A1 WO2013132512 A1 WO 2013132512A1 IN 2012000588 W IN2012000588 W IN 2012000588W WO 2013132512 A1 WO2013132512 A1 WO 2013132512A1
Authority
WO
WIPO (PCT)
Prior art keywords
microns
pharmaceutical formulation
particle size
raloxifene
raloxifene hydrochloride
Prior art date
Application number
PCT/IN2012/000588
Other languages
English (en)
Inventor
Bala Pasha MOHAMMED
Manoj JALAGAM
Original Assignee
Glochem Industries Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glochem Industries Limited filed Critical Glochem Industries Limited
Publication of WO2013132512A1 publication Critical patent/WO2013132512A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Definitions

  • the present invention relates to formulations containing benzothiophene compounds, especially raloxifene or pharmaceutical salts thereof, preferably a crystalline non-solvated raloxifene hydrochloride as the active pharmaceutical ingredient and a process for preparing a composition.
  • Raloxifene [6-hydroxy-2-(4-hydroxyphenyl)-benzothiophen-3-yl]-[4-[2-(l -piperidyl) ethoxy] phenyl]-methanone, is disclosed in U.S. Pat. No. 4,418,068 and is a selective estrogen receptor modulator and widely used for the treatment and prevention of osteoporosis in postmenopausal women.
  • Raloxifene is a pharmaceutically active compound, indicated for treatment and/or prevention of osteoporosis in women.
  • it is used in the form of a hydrochloride salt and is marketed, e.g., under the brand name Evista® by Eli Lilly. .
  • U.S. Patent Nos. 5,81 1 , 120 and 5,972,383 disclose solid oral compositions comprising raloxifene in combination with a surfactant, polyvinylpyrrolidone, and a water soluble diluent, wherein surfactants comprise sorbitan fatty acid esters or polyoxyethylene sorbitan fatty acid esters, and the water soluble diluent is a polyol or a sugar.
  • U.S. Patent No. 6,458,81 1 describes pharmaceutical compositions containing raloxifene having a mean particle size less than about 25 .mu.m, wherein about 90% of raloxifene particles have a size of less than about 50 .mu.m.
  • U.S. Patent No. 6,894,064 discloses a pharmaceutical composition
  • a pharmaceutical composition comprising a) raloxifene in particulate form, said particles having a mean particle size of less than about 25 .mu.m, with at least about 90% of said particles have a size of less than about 50 microns; b) a surfactant; and c) a water-soluble diluent.
  • U.S. Patent Publication 20100003319 describes pharmaceutical composition of raloxifene or a pharmaceutically acceptable salt having a mean particle size of at least about 25 [mu]m, preferably 25 [mu]m to 125 [mu]m, most preferably 30 [mu]m to 50 [mu]m.
  • PCT application WO2009146097 discloses pharmaceutical formulation of raloxifene hydrochloride having mean particle size 30 to 75 [mu]m and 90 % of particles do not exceed 60 to 150 [mu]m, having non-ionic surfactant and water-insoluble diluent, antioxidant, and a disintegrant.
  • US patent publication US20060099252 discloses compressed pharmaceutical dosage form wherein an active ingredient may be Raloxifene, oxcarbazepine or atorvastatin, pharmaceutically acceptable salts, isomers and derivatives thereof, and mixtures composition comprising starch.
  • US patent publication US20090162444 discloses pharmaceutical composition
  • pharmaceutical composition comprising raloxifene hydrochloride having mean particle size of 5 to 20 [mu]m, 95% of particles are ⁇ 50 [mujm, a mixed cellulose excipient and a disintegrant, wherein the composition is devoid of povidone or starch.
  • US8030330 discloses a pharmaceutical composition
  • a pharmaceutical composition comprising a 60 mg dose of raloxifene hydrochloride salt having a mean particle size of less than about 25 microns, at least about 90% of said particles having a size of less than about 50 microns and one or more pharmaceutically acceptable carriers, diluents, or excipients.
  • the bioavailability of raloxifene hydrochloride is quite low.
  • a cursory review of prior art indicates that several attempts have been made to increase bioavailability in pharmaceutical formulations. Among which one attempt is by improving a physical form of Raloxifene i.e., decreasing particle size to increase its dissolution along with enhanced bioavailability. Even an amorphous raloxifene hydrochloride was also disclosed with enhanced bioavailability.
  • raloxifene has poor solubility and poor bioavailability, there exists a need for developing improved formulations which does not require micronized raloxifene and still show improved dissolution even with higher particle size of raloxifene hydrochloride.
  • the present invention provides a pharmaceutical composition which includes a novel excipient along with crystalline non-solvated raloxifene hydrochloride having a mean particle size of at least about 25 microns & 90 percent of particles having about .50 to about 80 microns, which shows better dissolution.
  • novel pharmaceutical composition comprising,
  • raloxifene hydrochloride having a mean particle size of at least about 25 microns & 90 percent of particles having about 50 to about 80 microns;
  • d) optionally at least one water insoluble diluent optionally at least one water insoluble diluent.
  • pharmaceutical formulation comprising a crystalline non-solvated raloxifene hydrochloride having a mean particle size of at least about 25 microns & 90 percent of particles having about 50 to about 80 microns, a surfactant & a water soluble diluent and optionally at least one water insoluble diluent.
  • the surfactant is selected from ionic or non-ionic surfactant.
  • One preferable surfactant is polysorbate 80.
  • the water soluble diluent for the purpose of the present invention is an amino acid and/or sugar.
  • One preferable amino acid is glycine and one preferable sugar is lactose monohydrate.
  • the pharmaceutical composition is a mixture of:
  • One water insoluble diluent is Micro crystalline cellulose.
  • the preferred embodiment of the invention comprises a crystalline non- solvated raloxifene hydrochloride as an active ingredient; at least orte surfactant, preferably polysorbate 80; a water soluble diluent such as an amino acid !iid/or sugar, preferably glycine, preferably lactose monohydrate; optionally at leasB one water insoluble diluent, preferably micro crystalline cellulose.
  • the pharmaceutical composition of the present invention exhibits higher dissolution even with raloxifene hydrochloride having mean particle size of at least about 25 microns & 90 percent of particles having about 50 to about 80 microns, which has been achieved with the use of hither to unknown excipients.
  • Such dissolution of raloxifene is achieved with the inclusion of a water soluble diluent preferably glycine and/or lactose monohydrate into the tablet or capsule formulation.
  • Another aspect of present invention relates to process for the preparation of pharmaceutical formulation comprising a crystalline non-solvated raloxifene hydrochloride having a mean particle size of at least about 25 microns & 90 percent of particles having about 50 to about 80 microns, wherein the dissolving of raloxifene hydrochloride & surfactant is carried out in a solvent mixture specifically mixture of water and acetone.
  • Another aspect of present invention relates to process for the preparation of pharmaceutical formulation comprising a crystalline non-solvated raloxifene hydrochloride having a mean particle size of at least about 25 microns & 90 percent of particles having at least 50 microns, wherein the dissolving of raloxifene hydrochloride & surfactant is carried out in a solvent mixture specifically mixture of water and acetone.
  • a further aspect of present invention relates to process for the preparation of pharmaceutical formulation
  • process for the preparation of pharmaceutical formulation comprising a step of blending crystalline non-solvated raloxifene hydrochloride having a mean particle size of about 25 to about 40 microns & 90 percent of particles having about 50 to about 80 microns along with a water soluble diluent and disintegrant with a mixture of surfactant & binder solution, which is dried and further compressed into tablets.
  • the present invention provides a pharmaceutical composition which includes a novel excipient along with crystalline non-solvated raloxifene hydrochloride having a mean particle size of at least about 25 microns & 90 percent of particles having about 50 to about 80 microns, which shows better dissolution.
  • the present invention provides novel pharmaceutical composition with higher dissolution, which comprises, a) raloxifene hydrochloride having a mean particle size of at least about 25 microns & 90 percent of particles having about 50 to about 80 microns
  • the surfactant is selected from ionic or non-ionic surfactant.
  • One preferable surfactant is polysorbate 80.
  • the water soluble diluent for the purpose of the present invention is an amino acid or sugar
  • One preferable amino acid is glycine. Use of other suitable amino acids also falls within the purview of this invention.
  • One preferable sugar is lactose monohydrate. Use of other suitable sugars also falls within the purview of this invention.
  • the pharmaceutical composition of the present invention optionally comprises at least one water insoluble diluent.
  • One preferable water insoluble diluent is micro crystalline cellulose.
  • a person skilled in the art may also select variety of diluents, those are water soluble to achieve the instant invention.
  • a novel pharmaceutical composition disclosed herein comprises a crystalline non-solvated raloxifene hydrochloride as an active ingredient; at least one surfactant, preferably polysorbate 80; a water soluble diluent such as an amino acid, and/or sugar, preferable amino acid is glycine, preferable sugar is lactose monohydrate; optionally at least one water insoluble diluent, preferably micro crystalline cellulose;.
  • manufacturing process of pharmaceutical formulation according to the invention comprises
  • step (a) dissolving a crystalline non-solvated raloxifene hydrochloride having a mean particle size of at least about 25 microns & 90 percent of particles having about 50 to about 80 microns, & surfactant in a solvent mixture specifically acetone-water mixture, b) spraying the mixture of step (a) on to the water soluble diluent, preferably glycine, c) blending with extra granular material, d) compressing into tablets, and
  • the extra granular material is selected from Micro crystalline cellulose, Crosspovidone, croscarmellose sodium and/or low substituted hydroxy propyl cellulose.
  • the dissolution of crystalline non-solvated raloxifene hydrochloride is achieved upto 95 % in just 30 minutes, where the formulation comprises the dissolving of raloxifene hydrochloride in acetone water ' mixture with higher particle size.
  • manufacturing process of pharmaceutical composition comprising aqueous granulation of crystalline non-solvated raloxifene hydrochloride having a mean particle size of about 25 to about 40 microns & 90 percent of particles having about 50 to about 80 microns, along with a water soluble diluent such as an amino acid, preferably glycine and/or sugar preferably lactose monohydrate and a disintegrant with a mixture of surfactant specifically polysorbate 80 & binder solution, followed by drying & blending with extra granular materials and compressing into tablets. The tablets thus obtained are finally coated with opadry dispersion in water.
  • the binder used according to the invention is selected from Povidone k29/32, hydroxy propyl methyl cellulose and/or hydroxy propyl cellulose.
  • the disintegrant used according to the invention is selected from Cross Povidone XL, crosscarmellose sodium and/or low substituted hydroxy propyl cellulose.
  • the dissolution of crystalline non-solvated raloxifene hydrochloride is achieved upto 97.3 % in just 30 minutes, where the formulation comprises aqueous granulation of raloxifene hydrochloride of higher particle size & glycine and/or lactose monohydrate.
  • Particle size distribution of raloxifene hydrochloride is tested using a Horiba Laser Scattering Particle Size distribution analyzer LA-950, where mean particle size is observed to be at least about 25 microns; and 90% of particles have sizes about 50 to about 80 microns.
  • the present invention also provides methods of using pharmaceutical formulations according to the invention for preventing and/or treating osteoporosis in postmenopausal women.
  • the following examples, which include preferred embodiments, will serve to illustrate the practice of this invention, it being understood that the particulars shown are by way of example and for purpose of illustrative discussion of preferred embodiments of the invention.
  • Crystalline non-solvated raloxifene hydrochloride having mean particle size of at least about 25 microns and d90 of at least 50 microns, Povidone and polysorbate- 80 were dissolved in acetone-purified water mixture in a ratio of 60:40. 2. The above solution was sprayed on to the mixture of Glycine and Crospovidone XL by using Fluid bed equipment.
  • step 2 Material of step 2 was granulated in Rapid mixer granulator with purified water and further dried.
  • the dried granulation material of above step was blended with extra granular material, Micro crystalline cellulose, Crospovidone XL and lubricated with magnesium stearate.
  • step 4 The resultant blend of step 4 was compressed into tablets and
  • step 2 Material of step 2 was granulated in Rapid mixer granulator with purified water and further dried.
  • step 4 The resultant blend of step 4 was compressed into tablets and
  • Crystalline non-solvated raloxifene hydrochloride having mean particle size of about 25 to about 40 microns and d90 of about 50 to about 80 microns, Crosspovidone XL and glycine were granulated in rapid mixer granulator along with the solution of step 1 and dried.
  • step 3 The dried granules of step 2 was blended with extra granular material, Micro crystalline cellulose, cross povidone and lubricated with magnesium stearate.
  • step 4 The resultant blend of step 3 was compressed into tablets and
  • step 3 The dried granules of step 2 was blended with Cross Povidone and lubricated with magnesium stearate.
  • step 4 The resultant blend of step 3 was compressed into tablets and .
  • step 2 Material of step 2 was granulated in Rapid mixer granulator with purified water and further dried.
  • step 4 The resultant blend of step 4 was compressed into tablets and
  • step 2 Material of step 2 was granulated in Rapid mixer granulator with purified water and further dried.
  • step 4 The resultant blend of step 4 was compressed into tablets and

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une nouvelle composition pharmaceutique comprenant du chlorhydrate de raloxifène cristallin non solvaté, présentant une dissolution améliorée même à une plus grande taille de particules de chlorhydrate de raloxifène, présentant une taille moyenne de particules d'au moins environ 25 microns et 90 % des particules mesurant environ 50 à environ 80 microns, et un procédé pour sa préparation.
PCT/IN2012/000588 2012-03-05 2012-09-06 Composition pharmaceutique de chlorhydrate de raloxifène WO2013132512A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN812/CHE/2012 2012-03-05
IN812CH2012 2012-03-05

Publications (1)

Publication Number Publication Date
WO2013132512A1 true WO2013132512A1 (fr) 2013-09-12

Family

ID=49116044

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2012/000588 WO2013132512A1 (fr) 2012-03-05 2012-09-06 Composition pharmaceutique de chlorhydrate de raloxifène

Country Status (1)

Country Link
WO (1) WO2013132512A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160050325A (ko) * 2014-10-29 2016-05-11 일동제약주식회사 라록시펜 염산염 신규 용매화물 및 이를 사용한 라록시펜 염산염 일수화물의 제조방법
CN113842369A (zh) * 2021-10-29 2021-12-28 澳美制药(苏州)有限公司 盐酸雷洛昔芬片剂及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972383A (en) * 1994-03-02 1999-10-26 Eli Lilly And Company Solid orally administerable raloxifene hydrochloride pharmaceutical formulation
US20060099252A1 (en) * 2004-11-10 2006-05-11 Ilan Zalit Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
US20100003319A1 (en) * 2008-07-02 2010-01-07 Glenmark Generics Ltd. Raloxifene immediate release tablets
WO2011000581A2 (fr) * 2009-07-02 2011-01-06 Synthon B.V. Composition de raloxifène

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972383A (en) * 1994-03-02 1999-10-26 Eli Lilly And Company Solid orally administerable raloxifene hydrochloride pharmaceutical formulation
US20060099252A1 (en) * 2004-11-10 2006-05-11 Ilan Zalit Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
US20100003319A1 (en) * 2008-07-02 2010-01-07 Glenmark Generics Ltd. Raloxifene immediate release tablets
WO2011000581A2 (fr) * 2009-07-02 2011-01-06 Synthon B.V. Composition de raloxifène

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160050325A (ko) * 2014-10-29 2016-05-11 일동제약주식회사 라록시펜 염산염 신규 용매화물 및 이를 사용한 라록시펜 염산염 일수화물의 제조방법
KR102305091B1 (ko) 2014-10-29 2021-09-27 일동제약(주) 라록시펜 염산염 신규 용매화물 및 이를 사용한 라록시펜 염산염 일수화물의 제조방법
CN113842369A (zh) * 2021-10-29 2021-12-28 澳美制药(苏州)有限公司 盐酸雷洛昔芬片剂及其制备方法

Similar Documents

Publication Publication Date Title
EP2068839B1 (fr) Composition pharmaceutique comprenant de la nilotinib ou son sel
JP2022510732A (ja) ニロチニブの医薬組成物
EP2242483B1 (fr) Composition de raloxifène
WO2013030803A1 (fr) Sel de choline d'un composé anti-inflammatoire à base de cyclobutènedione substitué
US11273128B1 (en) Elagolix formulation
CA2801020A1 (fr) Preparation pharmaceutique stable contenant du telmisartan et de l'hydrochlorothiazide
KR101237646B1 (ko) 생체이용률이 개선된 셀레콕시브 함유 고체 분산체, 이를 포함하는 약학 조성물 및 이의 제조방법
AU2007338359A1 (en) Pharmaceutical formulation comprising neurokinin antagonist
PT2468361E (pt) Formulações de vildagliptina
EP2448562B1 (fr) Composition de raloxifène
EP2701689B1 (fr) Compositions pharmaceutiques de raltégravir, procédés de préparation et utilisation de celles-ci
WO2005027876A1 (fr) Compositions pharmaceutiques de benzimidazole et leurs procedes de preparation
WO2014058047A1 (fr) Procédé de production de préparation pharmaceutique contenant un inhibiteur calcique / antagoniste du récepteur d'angiotensine ii
US7959948B2 (en) Pharmaceutical composition of quetiapine fumarate
US20100086590A1 (en) Novel stable pharmaceutical compositions of clopidogrel bisulfate and process of preparation thereof
WO2013132512A1 (fr) Composition pharmaceutique de chlorhydrate de raloxifène
WO2019192195A1 (fr) Composition pharmaceutique contenant du dabigatran étexilate et son procédé de préparation
US20100003319A1 (en) Raloxifene immediate release tablets
US11260055B2 (en) Oral pharmaceutical composition of lurasidone and preparation thereof
EP2846778B1 (fr) Formulation posologique solide orale de [(1s)-1-{[(2s,4r)-4-(7-chloro-4-méthoxyisoquinolin-1-yloxy)-2-({(1r,2s)-1-[(cyclopropylsulfonyl)carbamoyl]-2-éthénylcyclopropyl}carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-diméthylpropyl]carbamate de 1,1-diméthyléthyle
CA3187241A1 (fr) Compositions pharmaceutiques comprenant du ribociclib
WO2010062996A2 (fr) Composition de ribavirine
AU2012303675A1 (en) Choline salt of an anti - inflammatory substituted cyclobutenedione compound
WO2005027881A2 (fr) Quinapril

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12870413

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12870413

Country of ref document: EP

Kind code of ref document: A1